Neovacs S.A.
ALNEV.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.00 | 0.00 | 0.00 |
| FCF Yield | -2.07% | -0.30% | 0.00% | 0.00% |
| EV / EBITDA | -6.80 | -173.69 | -0.32 | 1.47 |
| Quality | ||||
| ROIC | -35.84% | -14.12% | -11.57% | -16.55% |
| Gross Margin | 11.58% | -1,266.26% | -563,037.68% | -33,620.50% |
| Cash Conversion Ratio | 0.11 | 0.22 | 1.25 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 590.66% | 186.87% | -66.58% | – |
| Free Cash Flow Growth | -73.91% | 54.00% | 55.14% | -75.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.06 | -0.32 | 1.47 |
| Interest Coverage | -0.33 | -6.86 | -11.00 | -3.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,051.79 | 1,802.62 | 593,639.24 | 25,777.25 |